Research & Educational Use Only. Not medical advice. Consult a healthcare professional before beginning any protocol.
Melanocortin Receptor AgonistEvidence Grade: A (FDA-Approved as Vyleesi)
PT-141 (Bremelanotide) Protocol Guide
PT-141 (Bremelanotide) is a melanocortin-4 receptor (MC4R) agonist that works through central nervous system pathways to modulate sexual arousal and desire. Unlike PDE5 inhibitors, PT-141 acts on the brain rather than peripheral vasculature. FDA-approved as Vyleesi, this protocol covers reconstitution from a 10mg vial, as-needed subcutaneous dosing at 1-2mg, timing 30-60 minutes before desired effect, nausea management strategies, and frequency limitations.
Protocol Overview
- Compound
- PT-141 (Bremelanotide)
- Category
- Melanocortin-4 Receptor Agonist
- Mechanism
- Activates MC4R in the CNS to modulate arousal pathways. Acts centrally, not peripherally like PDE5 inhibitors
- Molecular Weight
- 1,025.2 Da
- Half-Life
- ~2-4 hours
- Vial Size
- 10mg lyophilized powder
- Route
- Subcutaneous injection
- Frequency
- As needed (max 1x/24hrs, 8x/month)
- Cycle
- As needed (not a daily protocol)
Dosing Protocol
| Protocol | Dose | Timing | Limits |
|---|---|---|---|
| Standard | 1.75 mg | 30-60 min before desired effect | Max 1x per 24 hours |
| First-time test | 0.5-1.0 mg | Test dose for tolerance | Assess nausea response |
| Adjusted | 1.0-2.0 mg | Based on individual response | Max 8 doses per month |
Important: PT-141 is NOT a daily protocol. Use as-needed only. Start low to assess nausea tolerance.
Reconstitution
Setup
- PT-141 10mg vial
- 2mL bacteriostatic water
- Concentration: 5 mg/mL
Dose Chart
| Dose | Volume | Units |
|---|---|---|
| 0.5 mg | 0.10 mL | 10 units |
| 1.0 mg | 0.20 mL | 20 units |
| 1.75 mg | 0.35 mL | 35 units |
| 2.0 mg | 0.40 mL | 40 units |
Administration
Injection
- Abdomen: 2 inches from navel (preferred)
- Thigh: Outer mid-thigh
- Site does not affect efficacy
Timing
- 30-60 minutes before desired effect
- Effects last 6-12 hours
- Max 1 dose per 24 hours
- Max 8 doses per month
- Refrigerate after reconstitution
Onset Timeline
30-60 min
Onset. CNS melanocortin activation. Mild flushing and warmth. Nausea possible (most common side effect).
1-6 hours
Peak effect window. Enhanced arousal via central nervous system pathways.
6-12 hours
Gradual tapering. Some report prolonged duration up to 12 hours.
24+ hours
Effects fully resolved. Safe to redose after 24 hours if needed.
Side Effects & Nausea Management
Common
- Nausea (up to 40% of subjects)
- Flushing / warmth
- Headache
- Injection site reactions
- Mild skin darkening with repeat use
Nausea Management
- Start with low test dose (0.5-1.0mg)
- Take ondansetron (Zofran) 30 min prior
- Light meal 1-2 hours before dosing
- Stay hydrated
- Nausea typically resolves in 1-2 hours
Contraindications: Uncontrolled hypertension, cardiovascular disease. Monitor blood pressure with first use.
Blood Work
| Panel | Markers | Timing |
|---|---|---|
| Cardiovascular | Blood pressure monitoring | Before/after first use |
| Hormonal | Testosterone/estrogen panel | Baseline |
| Basic | CBC, CMP | Baseline |
Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Paid partnership · Learn more